

LATAM LOWERS LDL-C

NCT06501443

Status	RECRUITING
Phase	Phase 4
Sponsor	Novartis Pharmaceuticals
Enrollment	520 participants

Key Eligibility Criteria

Inclusion (6)

- Admitted for MI (Type 1 NSTEMI or STEMI), urgent (i.e., non-elective) coronary revascularization (PCI or CABG) or confirmed ischemic stroke.
- Stable patient: Patient will be considered stable if they did not suffer cardiac arrest at presentation or if in the last 24 hours before randomization:
- Was not in cardiogenic shock.
- Did not required invasive hemodynamic, inotropic or vasopressor support.
- Participants are required to be eligible for receiving inclisiran in accordance to approved local label.

... and 1 more (see full listing online)

Exclusion (5)

- Currently on PCSK9i therapy (within last 3 months)
- Current participation in another clinical study with another study drug
- Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Baseline Visit
- Pregnant or nursing (lactating) women
- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception

Locations (11 total)

Novartis Investigative Site, Corrientes, Argentina
Novartis Investigative Site, Salvador, Estado de Bahia, Brazil
Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil
... and 8 more locations